Manuel Ozambela

Dr. Manuel Ozambela

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
Niki Zacharias MillwardNiki Zacharias Millward
Niki Zacharias Millward
MOManuel Ozambela
Manuel Ozambela
MKMenuka Karki
Menuka Karki
RHRong He
Rong He
PCPankaj K. Chauhan
Pankaj K. Chauhan
Pavlos MsaouelPavlos Msaouel
Pavlos Msaouel
Renal medullary carcinoma (RMC) and fumarate hydratase (FH)–deficient renal cell carcinoma (RCC) are rare and highly aggressive cancers. Although the combination of VEGF inhibition by bevacizumab and EGFR inhibition by erlotinib is clinically used for both diseases, the differential effect of each component has not been investigated. Transcriptomic profiling revealed that RMC and FH-deficient tumor tissues demonstrate increased EGFR but not VEGF expression compared with adjacent normal kidney. Subsequent in vitro studies revealed that RMC and FH-deficient cell lines are sensitive to erlotinib treatment, whereas clear-cell RCC cell lines are resistant. We developed patient-derived xenograft (PDX) models of tumors exposed to first-line therapies to represent treatment-experienced RMC and FH-deficient RCC models. These models were then used to determine tumor growth response to angiogenesis inhibition by bevacizumab alone or in combination with erlotinib. The FH-deficient RCC PDX model responded to either bevacizumab or erlotinib alone or in combination, whereas the RMC PDX model responded only to erlotinib, consistent with clinical and preclinical data suggesting that RMC is refractory to angiogenesis inhibition. Statistically higher expression of EGFR was observed in the RMC PDX model compared with the FH-deficient model, whereas higher phosphorylated tyrosine-416 SRC expression was observed in the FH-deficient PDX model compared with the RMC model. Our preclinical data suggest that EGFR signaling differentially modulates tumor growth in RMC and FH-deficient RCC and that angiogenesis inhibition is a valid target in FH-deficient RCC but not RMC.

26 October 2025 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
MIMohamed Javid Raja Iyub
Mohamed Javid Raja Iyub
PPPushan Prabhakar
Pushan Prabhakar
DSDeerush Kannan Sakthivel
Deerush Kannan Sakthivel
ACAditi Chandrasekaran
Aditi Chandrasekaran
MOManuel Ozambela
Manuel Ozambela
MMMurugesan Manoharan
Murugesan Manoharan

16 September 2025 in Journal of Robotic Surgery
Verified
Journal Article
Closed access
PDF file
DSDeerush Kannan Sakthivel
Deerush Kannan Sakthivel
PPPushan Prabhakar
Pushan Prabhakar
MIMohamed Javid Raja Iyub
Mohamed Javid Raja Iyub
MOManuel Ozambela
Manuel Ozambela
MMMurugesan Manoharan
Murugesan Manoharan


3 November 2025
Verified
Other
Open access
Niki Zacharias MillwardNiki Zacharias Millward
Niki Zacharias Millward
MOManuel Ozambela
Manuel Ozambela
MKMenuka Karki
Menuka Karki
RHRong He
Rong He
PCPankaj K. Chauhan
Pankaj K. Chauhan
Pavlos MsaouelPavlos Msaouel
Pavlos Msaouel
Growth curves for subcutaneous UOK360 tumor-bearing mice treated with vehicle or erlotinib.

3 November 2025
Verified
Other
Open access
Niki Zacharias MillwardNiki Zacharias Millward
Niki Zacharias Millward
MOManuel Ozambela
Manuel Ozambela
MKMenuka Karki
Menuka Karki
RHRong He
Rong He
PCPankaj K. Chauhan
Pankaj K. Chauhan
Pavlos MsaouelPavlos Msaouel
Pavlos Msaouel
STR of original and patient tissue and preclinical models of FH-RCC1X and RMC32X.